Fierce Pharma September 7, 2023
By Nick Paul Taylor

PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get filled.

In recent years, the Big Pharma trade group has responded to criticisms of drug prices by running a string of ads about the effect of PBMs. PhRMA created the blueprint for the attack ads with the spots it ran in 2019 and 2021, and it returned for another round earlier this year in the wake of Congress’ vote to pass contentious drug pricing legislation.

The latest TV spot has the same structure as the two previous ads. In the new spot, titled “Middlemen Are...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Eli Lilly to invest $27B in manufacturing
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
Lilly expands US manufacturing build-out with $50B target
How AI Drug Manufacturing Is Changing the Game

Share This Article